论文部分内容阅读
[目的]观察单唾液酸四己糖神经节苷脂(monosialotetrahexosylganglioside,GM1)联合巴曲酶注射液治疗急性脑梗死的临床疗效。[方法]急性脑梗死(ACI)患者80例,随机分为治疗组(50例)和对照组(30例)。均给予一般治疗;治疗组在一般治疗基础上加用巴曲酶注射液联合单唾液酸四己糖神经节苷脂,观察临床疗效、神经功能缺损评分(NFDS)的改变。[结果]两组神经功能缺损评分均有所改善,但治疗组疗效明显优于对照组(P﹤0.05)。[结论]巴曲酶、单唾液四己糖神经节苷脂联合应用治疗急性脑梗死,疗效明显优于对照组。
[Objective] To observe the clinical efficacy of monosialotetrahexosylganglioside (GM1) combined with batroxobin in the treatment of acute cerebral infarction. [Methods] 80 patients with acute cerebral infarction (ACI) were randomly divided into treatment group (50 cases) and control group (30 cases). Were given general treatment; the treatment group on the basis of the general treatment with Batroxobin plus monosialotetrahexosyl ganglioside, clinical efficacy, neurological deficit score (NFDS) changes. [Results] The neurological deficit scores of both groups improved, but the therapeutic effect of the treatment group was obviously better than that of the control group (P <0.05). [Conclusion] The combination of batroxobin and mono-salivate tetrahexose ganglioside can effectively treat acute cerebral infarction. The curative effect is obviously better than that of the control group.